The FDA released draft guidance detailing the ethical considerations for pediatric clinical investigations and the application of 21 C.F.R. Part 50 Subpart D, which specifies additional safeguards for children. “Children are a vulnerable population who cannot consent for themselves and who therefore are afforded additional safeguards when participating in a clinical investiga... Read More